Indian drugmaker Mankind Pharma reported a lower first-quarter profit on Thursday, as mounting expenses outpaced strong ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

With 1 August fast approaching, we expect the Trump administration to announce pharmaceutical tariffs soon. We anticipate an ...

Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual ...

Basel researchers merge MHAT chemistry with enzymes, opening new pathways for greener pharmaceutical synthesis.

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

India's Torrent Pharma reported a 20% jump in its first-quarter profit on Monday, driven by demand for drugs used to treat ...

Moderna announced layoffs affecting 10% of its workforce amid government and competitive challenges to its vaccine business ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

PsyLabs’ extraction division is currently expanding its chemistry production area to ensure it consistently meets the growing demand for Ibogaine HCL, Psilocybin Isolate, and other 90% purity SKUs, ...

ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.

Detailed price information for Conduit Pharmaceuticals Inc (CDT-Q) from The Globe and Mail including charting and trades.